<?xml version="1.0" encoding="UTF-8"?>
<p>First, 
 <italic>regulation of cardiometabolic disease</italic>. Cardiometabolic comorbidities are associated with adverse COVID-19 outcomes. However, many patients with hypertension or diabetes mellitus, especially in resource-poor countries, demonstrate poor adherence to essential medications [
 <xref rid="B8" ref-type="bibr">8</xref>]. Furthermore, as it was suggested that ACE inhibitors and angiotensin receptor blockers have potentially harmful effects on COVID-19 outcome, individuals have been discontinuing treatments. Yet, thus far, no studies recommend discontinuing or altering treatment. Clinical societies strongly recommend individuals with a known history of the cardiometabolic disease to regulate their blood pressure and/or glucose levels by continuing prescribed treatments including, e.g., glucose self-checks and taking medications [
 <xref rid="B9" ref-type="bibr">9</xref>].
</p>
